

NOXXON PHARMA AG TO PRESENT AT BIO-EUROPE IN DUESSELDORF, GERMANY

Berlin, Germany, November 03, 2006 -- NOXXON Pharma AG (NOXXON), the next generation aptamer company and leader in Spiegelmer therapeutics, will present at BIO-Europe in Düsseldorf, Germany. The presentation is scheduled for November 8th at 12:45 pm in Room 26, Level 2 of the Congress Center Süd as part of the Discovery Section.

Dr. Steffen Helmling, NOXXON's Vice President of Business Development, will provide a corporate overview, including the current status of development of the company's lead compounds. NOXXON is currently assembling investors for a series C round of financing to support the pre-clinical and clinical development of NOXXON's lead compounds NOX-A12 for the treatment of diabetic retinopathy and NOX-E36 for the treatment of renal inflammation. In addition to developing its own products the company is looking to widen the application of its powerful drug discovery technology through licensing and partnering with members of community of the biotechnology and pharmaceutical industry.

About the event:

BIO-Europe provides an excellent forum for international decision makers from the biotechnology, pharmaceutical and financial sectors to meet and develop partnerships between their companies. For more information or a schedule of presentations visit: <http://www.ebdgroup.com/bioeurope>.

About NOXXON Pharma AG, the next generation aptamer company:

Based on one of the largest and best protected patent portfolio, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: <http://www.noxxon.net>

General contact: Esther Hildebrandt
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49 30 72 62 47 0
FAX: + 49 30 72 62 47 225
Email: ehildebrandt@noxxon.net